Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed FCX-013 for the potential treatment of scleroderma.
Matthew Gantz
Advertisement
President and chief executive officer, Castle Creek Biosciences
Articles by Matthew Gantz
Matthew Gantz, president and chief executive officer, Castle Creek Biosciences, discussed the company and its pipeline.
Advertisement
Latest Updated Articles
Assessing Gene Therapy in Recessive Dystrophic Epidermolysis BullosaFebruary 1st 2022
Targeting Unmet Needs in Rare Dermatologic Diseases With Gene TherapyFebruary 18th 2022
Advertisement
Advertisement